Jefferies initiates Alvotech stock coverage with buy rating on biosimilar pipeline
Jefferies initiated coverage on Alvotech (NASDAQ:ALVO) with a buy rating and $9 price target, citing its biosimilar pipeline and partnerships. The company reported Q2 2026 revenue of $106M, missing estimates, and faces debt and cash burn challenges. Barclays and BofA also initiated coverage with bullish ratings.
How this was made
The 30-second read
Why it matters
The new buy ratings and higher price targets could attract short‑term buying pressure.
Market read
ALVO may experience a short‑term rally on the fresh analyst upgrades.
What to watch
Manufacturing disruptions in Reykjavik may delay product launches.
Background
Analyst coverage initiations and upgrades are common catalysts for small‑cap biotech stocks.
Ticker impact
Jefferies initiates coverage on Alvotech with a buy rating and a $9 price target, also noting Barclays and BofA upgrades and new price targets.
likely upward pressure as investors price in the new buy rating and higher targets
Multiple analysts are raising ratings and targets, indicating improved outlook and prompting buying interest.
Market effects
Positive sentiment may lift other biosimilar and biotech peers.
European biotech sector could see modest gains.
Limited to niche biotech investors.
Counterpoint
The company faces cash burn and debt concerns that could limit upside.
Key entities
- companyAlvotech SA
Icelandic biosimilar developer listed on NASDAQ.
- analyst_firmJefferies
Initiated coverage with a buy rating.
